Clinical Trials Logo

Filter by:
NCT ID: NCT03112720 Terminated - Clinical trials for Postdural Puncture Headache

Therapeutic Epidural Patch Versus Pain Block in the Midface for Headache

Start date: September 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare a pain block in the midface, versus the traditional, more invasive, therapeutic epidural patch for the treatment of headaches

NCT ID: NCT03112642 Terminated - Clinical trials for Other Biomechanical Lesions of Upper Extremity

Nerve Stimulator for Patients With Upper Extremity Disease, Vascular or Orthopedic Surgery

Start date: November 2013
Phase: N/A
Study type: Interventional

To help determine if there is improved pain relief when a device that makes an arm muscle move (nerve stimulator) is used to place a needle in the area above the collarbone to prevent feeling of pain (anesthesia) of the upper arm.

NCT ID: NCT03111914 Terminated - Prostate Cancer Clinical Trials

Applications of Dual Energy CT in Patients With Osseous Metastases From Castrate-resistant Prostate Cancer

Start date: July 3, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to establish a more accurate and precise way to image (take pictures of) metastatic bone disease in patients with prostate cancer for staging and monitoring response to therapy. More specifically, the study aims to evaluate the capabilities of dual energy CT as a more precise and accurate tool for staging and monitoring of therapy response in patients with osseous metastases from castrate-resistant prostate cancer. Bone metastases in prostate cancer patients are a clinical and diagnostic challenge to image. Sometimes very small metastatic bone lesions may only become detectable by imaging in response to therapy due to increased bone deposition during the first three months after therapy. Commonly used imaging tests (such as regular CT or bone scan) are unable to reliably tell the difference between increased bone deposition (therapy response) and growth of the lesion (progressive disease). This diagnostic challenge may have profound negative effects on patient management since it may require additional imaging before an accurate determination of tumor response can be made. An appropriate determination of tumor response is needed for appropriate management of prostate cancer. The investigators anticipate that the new imaging tested in this study (called dual energy CT) may provide additional critical information in this clinical and diagnostic challenge. Approximately 100 people with prostate cancer and metastatic bone disease will take part in this study. At enrollment, three months, and six months, they will will receive a non-enhanced (without contrast) dual energy CT scan of the chest, abdomen and pelvis before receiving their routine, clinical contrast-enhanced CT scan.

NCT ID: NCT03111823 Terminated - Clinical trials for Stage IV Colorectal Cancer

Exercise Program During Chemotherapy in Metastatic Colorectal Cancer

Start date: July 7, 2016
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well aerobic exercise works in improving quality of life and health-related outcomes in patients with stage IV colorectal cancer undergoing chemotherapy. Aerobic exercise during chemotherapy may improve quality of life and reduce fatigue and inflammation in the blood related to heart disease and diabetes in patients with stage IV colorectal cancer.

NCT ID: NCT03111264 Terminated - Pediatric Obesity Clinical Trials

Building Blocks for Healthy Preschoolers

Start date: June 17, 2016
Phase: N/A
Study type: Interventional

Pediatric obesity, a defining health problem of the century, leads to long-term health disparities. This application evaluates strategies to prevent health disparities early in life by developing environmental wellness-related interventions focused on child-care center staff and families. Childcare centers provide an excellent opportunity to build healthy dietary and physical activity lifestyle habits and avoid the rapid weight gain that leads to health disparities. Building on a statewide survey among childcare centers and a pilot evaluation of an environmental intervention, this 3-cell randomized trial evaluates the impact of a staff-led wellness intervention and a staff-led and family-focused intervention, against a control condition.

NCT ID: NCT03110900 Terminated - Clinical trials for Agitation,Psychomotor

Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation

loxapine
Start date: September 30, 2017
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to determine the noninferiority of inhaled loxapine compared to intramuscular haloperidol/lorazepam on agitation reduction at 120 minutes.

NCT ID: NCT03110575 Terminated - PTSD Clinical Trials

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

Start date: June 20, 2017
Phase: Phase 3
Study type: Interventional

This is an open-label, extension trial designed to evaluate safety over 12 additional weeks of TNX-102 SL therapy taken daily at bedtime for the treatment of PTSD. Patients recruited into this trial are those who have successfully completed the double-blind lead-in study.

NCT ID: NCT03110549 Terminated - Clinical trials for Human Immunodeficiency Virus

Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

Start date: November 21, 2016
Phase: Phase 1
Study type: Interventional

The study is a Phase 1, randomized, double-blinded, placebo-controlled, sequential single dose escalation safety, tolerability and pharmacokinetic study of subcutaneous and intramuscular TMB-607 administered to HIV-negative volunteers.

NCT ID: NCT03110354 Terminated - Clinical trials for Leukemia, Myeloid, Acute

DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

Start date: April 5, 2017
Phase: Phase 1
Study type: Interventional

This research study tests an investigational drug called DS-3201b. An investigational drug is a medication that is still being studied and has not yet been approved by the United States Food and Drug Administration (FDA). The FDA allows DS-3201b to be used only in research. It is not known if DS-3201b will work or not. This study consists of two parts. The first part (Part 1) is a dose escalation that will enroll subjects with AML or ALL that did not respond or no longer respond to previous standard therapy. The purpose of Part 1 of this research study is to determine the highest dose a patient can tolerate or recommended dose of DS-3201b that can be given to subjects with AML or ALL. Once the highest tolerable dose is determined, additional subjects will be enrolled at that dose into Part 2 of the study.

NCT ID: NCT03110107 Terminated - Advanced Cancer Clinical Trials

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Start date: May 4, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether BMS-986218 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors.